Uncoupling of inflammation and destruction in rheumatoid arthritis: Myth or reality?

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 995-999

  Van Den Berg, Wim B ^a   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR;

ANTIGEN ANTIBODY COMPLEX; CARTILAGE DEGENERATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; JOINTS; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17244370590     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20981     Document Type: Editorial

References (34)

1. Smolen JS, Han C, Bala M, Maini R, Kalden J, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. Arthritis Rheum 2005;52:1020-30.
2. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
3. Van Lent PL, Nabbe K, Blom AB, Holthuysen AE, Sloetjes A, van de Putte LB, et al. Role of activatory Fcγ RI and Fcγ RIII and inhibitory Fcγ RII in inflammation and cartilage destruction during experimental antigen induced arthritis. Am J Pathol 2001;159:2309-20.
4. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
5. Kirwan JR. The synovium in rheumatoid arthritis: evidence for (at least) two pathologies [editorial]. Arthritis Rheum 2004;50:1-4.
6. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.
7. Nakashima T, Wada T, Penniger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-7.
8. Lubberts E, Oppers-Walgreen B, Pettit AR, van den Bersselaar L, Joosten LA, Goldring SR, et al. Increase in expression of receptor activator of nuclear factor κB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002;46:3055-64.
9. Romas E, Gillespie MT, Martin TJ. Involvement of RANK ligand and TNF-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6.
10. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNF-α-mediated increase in CD11 (hi) osteoclast precursors but is essential for mature osteoclast formation in TNF-α-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-13.
11. high osteoclast precursors in tumor necrosis factor α-transgenic mice. Arthritis Rheum 2004;50:265-76.
12. Ito K, Udagawa N, Kobayashi K, Suda K, Li X, Takami M, et al. Lipopolysaccharide promotes the survival of osteoclasts via TLR-4. J Immunol 2003;170:3688-95.
13. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
14. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-51.
15. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
16. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
17. Lubberts E, Joosten LA, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-710.
18. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
19. Van den Berg WB. Arguments for IL-1 as a target in chronic arthritis. Ann Rheum Dis 2000;59 Suppl I:i81-4.
20. Van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001;3:18-26.
21. Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996;39:797-809.
22. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001;107:1519-27.
23. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for IL-1 and TNF in antibody induced arthritis. J Exp Med 2002;196:77-85.
24. Van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
25. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
26. Van Leeuwen MA, van Rijswijk MH, van der Heijde DM, te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993;32 Suppl 3:9-13.
27. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified Disease Activity Scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. Flendrie M, Creemers MC, van Riel PL. Two strategies to adjust inflimab therapy in case of insufficient response. Ann Rheum Dis 2004;63 Suppl 1:S301.
30. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiological progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:2082-93.
31. Swinkels HL, Laan RF, van 't Hof MA, van der Heijde DM, de Vries N, van Riel PL. Modified Sharp method: factors influencing reproducibility and variability. Semin Arthritis Rheum 2001;31:176-90.
32. Van der Heijde D, Boonen A, Boers M, Kostense P, van der Linden S. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford) 1999;38:1213-20.
33. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I IL-1 receptor acts in series with TNF to induce arthritis in TNF transgenic mice. Eur J Immunol 1995;25:1794-7.
34. Edwards JC, Szczepanski L, Szechinski J, Filipowics-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2546-8.